Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to a new study led by UCL and University of Oxford researchers.

The image depicts CAR T cells killing malignant bone marrow cells that are expressing mutant CALR, illustrated as a red ‘flag’ on the cell surface. © DrawImpacts
The image depicts CAR T cells killing malignant bone marrow cells that are expressing mutant CALR, illustrated as a red ‘flag’ on the cell surface. [Image credit: DrawImpacts]

MPNs are chronic blood cancers that begin when a mutation arises in the DNA of a blood stem cell. In one in three patients, the disease progresses to an advanced phase called myelofibrosis, where the bone marrow becomes scarred and unable to produce healthy blood. Rarely, MPN can transform to a leukaemia-like phase, where survival may be measured in months. For most patients, there are no curative treatments available.

CAR T-cell therapy works by reprogramming a patient’s own immune cells to target specific cells in the body and is already a successful treatment in other blood cancers. In this study, published in Science Translational Medicine, the engineered cells were designed to recognise a mutation found in around a third of MPN patients called CALR.

Using patient samples, a model that recreates human bone marrow in the lab, and studies in mice, the engineered CAR T-cells showed they could precisely kill cancer cells carrying the CALR mutation, without harming other blood cells.

When the team tested their research using lab-grown 3D mini bone marrows seeded with real myelofibrosis cells, they were able to show that the CAR T cells were even able to move into heavily scarred tissue (fibrosis) and kill the cancer cells.

One of the senior authors on the study, Professor Beth Psaila, from the MRC Weatherall Institute of Molecular Medicine and Ludwig Institute for Cancer Research:

Our model is designed to recreate the real conditions in which these cancers grow, including the fibrosis and complex tissue structure that might present a challenge for treatments that depend on immune cells working. Seeing the CAR T cells find and kill the cancer cells in fibrotic marrow organoids was a highly encouraging step and gives us additional hope that this therapy may work in patients.

We hope this platform will speed up the development of safer, more effective immunotherapies for myelofibrosis and other blood cancers.

MPNs are classed as rare, but around 4,000 people are diagnosed with an MPN in the UK each year (about 8 in every 100,000 people), and around a third of these cases are trigged by mutations in CALR, with many more people already living with the disease.

The team is currently seeking funding for a planned first-in-human clinical trial, and hopes that if early clinical results are encouraging, wider access to this potentially transformative treatment will follow.

Read the full paper in Science Translational Medicine here: CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis

Similar stories

£520,000 grant to test treatment for haemophilia-related ankle arthritis

Dr Nikki Curry from the Radcliffe Department of Medicine, and Steph Taylor from the Oxford Haemophilia & Thrombosis Centre, have been awarded a clinical trial grant from the National Institute of Health and Care Research for Patient Benefit (NIHR RfPB) funding stream to improve treatment for the ankle arthritis caused by haemophilia.

Researchers highlight need for better sleep support for NHS shift workers

A new study led by researchers at the University of Oxford’s Radcliffe Department of Medicine, has found that many NHS staff working shifts experience sleep difficulties, with researchers calling for more accessible, evidence-based support to help staff manage sleep.

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Oxford-led research identifies a new therapeutic strategy to reverse established atrial fibrosis in atrial fibrillation

Researchers at the University of Oxford have identified a promising new RNA-based therapeutic approach that can reverse established atrial fibrosis. Atrial fibrosis is a major contributor to atrial fibrillation, the most common sustained cardiac arrhythmia worldwide.

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.

Similar stories

£520,000 grant to test treatment for haemophilia-related ankle arthritis

Dr Nikki Curry from the Radcliffe Department of Medicine, and Steph Taylor from the Oxford Haemophilia & Thrombosis Centre, have been awarded a clinical trial grant from the National Institute of Health and Care Research for Patient Benefit (NIHR RfPB) funding stream to improve treatment for the ankle arthritis caused by haemophilia.

Researchers highlight need for better sleep support for NHS shift workers

A new study led by researchers at the University of Oxford’s Radcliffe Department of Medicine, has found that many NHS staff working shifts experience sleep difficulties, with researchers calling for more accessible, evidence-based support to help staff manage sleep.

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Oxford-led research identifies a new therapeutic strategy to reverse established atrial fibrosis in atrial fibrillation

Researchers at the University of Oxford have identified a promising new RNA-based therapeutic approach that can reverse established atrial fibrosis. Atrial fibrosis is a major contributor to atrial fibrillation, the most common sustained cardiac arrhythmia worldwide.

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.